Loading
A phase 1 trial of Varsetatug masetecan run by CytomX Therapeutics, now recruiting.
First In Human Study of CX-2051 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06265688 by CytomX Therapeutics, with 160 participants planned, started 2024-04-02. Conditions recorded: Solid Tumor, Adult. Interventions recorded: CX-2051 and Bevacizumab.
Shares Varsetatug masetecan, CytomX Therapeutics and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/